Intervention with flutamide, an androgen receptor (AR) inhibitor, has confirmed that testosterone action via the AR mediates apoB-hyperlipoproteinemia and hypertriglyceridemia, and this appears to be independent of effects on insulin (110). This evidence concerns the gene AR and hyperlipoproteinemia.